首页> American heart journal> Rivaroxaban, a direct Factor Xa inhibitor, versus acetylsalicylic acid as thromboprophylaxis in children post-Fontan procedure: Rationale and design of a prospective, randomized trial (the UNIVERSE study).

Rivaroxaban, a direct Factor Xa inhibitor, versus acetylsalicylic acid as thromboprophylaxis in children post-Fontan procedure: Rationale and design of a prospective, randomized trial (the UNIVERSE study).

导出 LinkOut

翻译打印收藏纠错

第一作者： Liza Miriam,Pina

第一单位： Janssen Research and Development, LLC., Raritan, NJ 08869.

作者： Liza Miriam,Pina ^[1] ; Xiangwen,Dong ^[1] ; Liping,Zhang ^[1] ; Mahesh N,Samtani ^[1] ; Alan D,Michelson ^[2] ; Henri,Justino ^[3] ; Damien,Bonnet ^[4] ; Kevin C,Harris ^[5] ; John,Jefferies ^[6] ; Brian W,McCrindle ^[7] ; Jennifer S,Li ^[8]

作者单位： Janssen Research and Development, LLC., Raritan, NJ 08869. ^[1] Boston Children's Hospital, Boston, MA 02115. ^[2] Texas Children's Hospital, Houston, TX 77030. ^[3] Hôpital Necker-Enfants Malades, Paris 15, France. ^[4] Children's Heart Centre, BC Children's Hospital, Vancouver, BC V6H 3N1, Canada. ^[5] The Heart Institute, Cincinnati Children's Hospital Medical Centre, Cincinnati, OH 45229. ^[6] The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada. ^[7] Duke University Medical Center, Durham, NC 27710. Electronic address: jennifer.li@duke.edu. ^[8]